N4 Pharma Plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss results for the year ended 31 December 2020. Nigel talks us through the highlights of the year, updates us on the new refined strategy to focus on three work streams, explains what the Patent in relation to Nuvec means for the company and lets us know what investors can expect from N4 Pharma in the near future.
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
The business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, the company will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
